Boston Scientific Express Stent Potentially Threatened By Medinol Lawsuit
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's strategy to rely on its internally developed Express coronary stent platform as a viable alternative to a troubled relationship with stent partner Medinol may be jeopardized by the Israeli firm's April 5 lawsuit alleging that the Express R&D initiative constituted breach of contract by Boston Scientific.
You may also be interested in...
Medinol Was Boston Scientific’s First And Final Pipeline Partner, CFO Vows
Boston Scientific is extracting a painful lesson from its failed business relationship with former stent partner Medinol: never delegate manufacturing and R&D authority to another firm
Medinol Was Boston Scientific’s First And Final Pipeline Partner, CFO Vows
Boston Scientific is extracting a painful lesson from its failed business relationship with former stent partner Medinol: never delegate manufacturing and R&D authority to another firm
Boston Scientific, Medinol Coronary Stent IDE Approvals Precede Legal Duel
Medinol's April 2001 lawsuit alleging Boston Scientific's development of the Express stent constitutes a breach of contract will likely be heard in New York federal court by late summer